Research Team Publications
Professor George Kannourakis
MB, BS, B(Med)Sc, PhD, FRACP
Director
Professor George Kannourakis oversees all research and administrative operations at the Fiona Elsey Cancer Research Institute. As the Institute’s founding Director, he has shaped its scientific direction, culture, and community-centred approach since its earliest days — transforming Fiona’s dream into a world-class cancer research facility based in regional Victoria. With a career spanning more than four decades, George brings a wealth of expertise in cancer cell biology, immunology, and translational medicine. He holds a PhD from the University of Melbourne for research undertaken at the Walter and Eliza Hall Institute of Medical Research, and completed postdoctoral studies at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. Prior to relocating to Ballarat, he led the Cancer Research Unit at the Royal Children’s Hospital in Melbourne, while also treating paediatric oncology and haematology patients — a dual role that shaped his enduring commitment to bridging research and care. Alongside his leadership at FECRI, George has long served the Ballarat region as a practising medical oncologist and clinical haematologist, with appointments across St John of God Health Services, Ballarat Health Services, and visiting roles in Stawell, Ararat, Horsham and Melbourne. He is Adjunct Professor of Cancer Biology at Federation University and Professor of Medical Oncology at the University of Notre Dame Medical School. George’s research contributions span the biology of blood cancers, immune system modulation, and rare diseases like Langerhans Cell Histiocytosis. His vision has always been clear: to bring cutting-edge science to regional Australia, build strong collaborations, and foster a new generation of researchers — all without government funding, and all in the name of hope.
Publications
- Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma
Journal: Biology (Basel)
Date: 2026-09-02
- Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma
Journal: Cancers
Date: 2026-07-21
- Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion
Journal: Journal of Biomedical Science
Date: 2026-06-26
- Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
Journal: Annals of Oncology
Date: 2026-06-26
- Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion
Journal: J Biomed Sci
Date: 2026-06-21
- The Signaling Networks of TIM-3, TGF-β and STING in Glioblastoma
Journal: Cells
Date: 2026-05-29
- Synthetic Biology for Cancer Stem Cells
Journal: Springer Nature
Date: 2026-05-25
- Synthetic Biology in Precision Medicine and Nanotechnology
Journal: Springer Nature
Date: 2026-05-25
- Recent Developments in Single-Cell Transcriptomics
Journal: Springer Nature
Date: 2026-05-25
- Nanotechnology in the Generation and Analysis of Single Cells
Journal: Springer Nature
Date: 2026-05-25
- Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience
Journal: Am J Hematol
Date: 2026-04-08
- Correlation of Galectin Family Expression with Glioblastoma Progression and Survival
Journal: Int J Mol Sci
Date: 2025-12-01
- Enhanced Expression of Mitochondrial Magmas Protein in Ovarian Carcinomas: Magmas Inhibition Facilitates Antitumour Effects, Signifying a Novel Approach for Ovarian Cancer Treatment
Journal: Cells
Date: 2025-04-01
- The Role of TIM-3 in Glioblastoma Progression
Journal: Cells
Date: 2025-02-01
- Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets
Journal: Cancers (Basel)
Date: 2024-12-12
- Impact of Ligand Concentration on the Properties of Nucleic-Acid-Encapsulated MOFs and Inflammation Modulation in Prostate Cancer Cells
Journal: ACS Appl Bio Mater
Date: 2024-11-01
- Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
Journal: Cells
Date: 2024-10-01
- Advances in CRISPR/Cas systems-based cell and gene therapy
Journal: Epub
Date: 2024-08-11
- The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits
Journal: Journal of Biomedical Science
Date: 2024-02-01
- Interleukin-11/IL-11 Receptor Promotes Glioblastoma Cell Proliferation, Epithelial-Mesenchymal Transition, and Invasion
Journal: Brain Sci
Date: 2024-01-11
- Divergent molecular networks program functionally distinct CD8+ skin-resident memory T cells
Journal: Science
Date: 2023-12-01
- A three-stage developmental pathway for human Vγ9Vδ2 T cells within the postnatal thymus
Journal: Sci Immunol
Date: 2023-07-12
- Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
Journal: N Engl J Med
Date: 2023-06-11
- Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results
Journal: Cancer Journal
Date: 2023-06-01
- In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.
Journal: Cancers
Date: 2023-05-01
- The Interleukin-11/IL-11 Receptor Promotes Glioblastoma Survival and Invasion under Glucose-Starved Conditions through Enhanced Glutaminolysis.
Journal: International Journal Molecular Science
Date: 2023-02-01
- Low-Dose Palliative Chemotherapy Compared to Standard-Dose Chemotherapy for Poor-Prognosis Cancers Improves Overall Survival- A Single Institution Study.
Journal: Journal of Clinical Medicine
Date: 2023-02-01
- Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
Journal: Cancer Cell International
Date: 2023-02-01
- Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism
Journal: Journal of Translational Medicine
Date: 2022-12-11
- Does CD1a Expression Influence T Cell Function in Patients With Langerhans Cell Histiocytosis?
Journal: Front. Immunol
Date: 2022-12-08
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Journal: Ann Oncol
Date: 2022-10-11
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: 2022-10-01
- Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
Journal: Front Med (Lausaane)
Date: 2022-06-01
- Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions
Journal: Front Pediatr.
Date: 2022-06-01
- Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment
Journal: Frontiers in Oncology
Date: 2022-01-11
- Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral retention of tissue-resident lymphocytes
Journal: J Exp Med
Date: 2022-01-01
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Journal: N Engl J Med
Date: 2021-06-11
- Langerhans cell histiocytosis: A malignant myeloid neoplasm or disorder of immune regulation?
Journal: Acta Paediatrica
Date: 2021-06-01
- The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence
Journal: Cell Commun Signal
Date: 2021-05-11
- Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
Journal: Journal of Clinical Medicine
Date: 2021-05-01
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Journal: Journal of Experimental & Clinical Cancer Research
Date: 2021-04-11
- Determinants of Resistance to VEGF-TKI and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: 2021-04-08
- Patients with both Langerhans cell histiocytosis and Crohn’s disease highlight a common role of interleukin-23
Journal: Acta Paediatr.
Date: 2021-04-01
- TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
Journal: BMC Cancer
Date: 2020-10-08
- When Langerhans met Crohn- intestinal inflammation in disguise
Journal: Acta Paediatrica
Date: 2020-09-11
- Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
Journal: Scientific Reports
Date: 2020-08-08
- A Role for MAIT Cells in Colorectal Cancer
Journal: Frontiers in Immunology
Date: 2020-05-01
- Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity
Journal: Clinical Immunology
Date: 2020-04-01
- Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods
Journal: Cells
Date: 2020-03-08
- Chronically stimulated human MAIT cells are unexpectedly potent IL-13 producers
Journal: Immunology & Cell Biology 2019
Date: 2019-07-01
- Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer
Journal: The Oncologist
Date: 2019-04-11
- Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer.
Journal: Cancers
Date: 2019-02-08
- Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis
Journal: Scientific Reports
Date: 2018-12-01
- Epithelial-to-mesenchymal transition as a robust biomarker and a novel strategy to enhance response to immune checkpoint blockade and targeted therapy in patients with metastatic renal cell carcinoma
Journal: Asia-pacific Journal of Clinical Oncology
Date: 2018-11-12
- Tumour Microenvironment and Metabolic Plasticity in Cancer and Cancer Stem Cells: Perspectives on Metabolic and Immune Regulatory Signatures in Chemoresistant Ovarian Cancer Stem Cells.
Journal: Seminars in Cancer Biology
Date: 2018-07-08
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Journal: N Engl J Med
Date: 2018-06-11
- A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis
Journal: Clinical Immunology
Date: 2018-06-01
- Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Journal: N Engl J Med
Date: 2018-04-11
- Momelotinib reduces cancer stem cell load leading to a decreased tumor burden and a prolonged disease-free remission period in a mouse model of human ovarian cancer
Journal: Oncotarget
Date: 2018-03-12
- Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
Journal: Oncotarget
Date: 2018-03-01
- The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.
Journal: International Journal of Molecular Sciences Review
Date: 2018-01-01
- Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.
Journal: Gastric Cancer
Date: 2017-08-11
- Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling
Journal: Scientific Reports
Date: 2017-04-12
- Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer
Journal: Advances in Current Drug Targets, Vol 3, Bentham Science Publishers
Date: 2016-12-12
- Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
Journal: Haematologica
Date: 2016-11-11
- Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Journal: N Engl J Med
Date: 2016-10-11
- Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.
Journal: Scientific Reports
Date: 2016-07-08
- Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells
Journal: Scientific Reports
Date: 2016-07-01
- Use of Suppression Subtractive Hybridization for Viral Diagnostics
Journal: British Journal Virology
Date: 2016-05-19
- Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.
Journal: Onco Targets Ther
Date: 2016-05-11
- Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Journal: Ann Oncol
Date: 2016-02-11
- Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?
Journal: BMJ Case Rep
Date: 2016-01-11
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Journal: Lancet
Date: 2015-12-11
- Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice.
Journal: Arch Virol
Date: 2015-09-01
- An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia.
Journal: International Immunopharmacol
Date: 2015-04-11
- EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
Journal: Ann Oncol
Date: 2015-02-11
- Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.
Journal: PLoS One
Date: 2014-10-01
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Journal: The New England Journal of Medicine
Date: 2014-07-11
- The glucocorticoid receptor 1A3 promoter correlates with high sensitivity to glucocorticoid-induced apoptosis in human lymphocytes.
Journal: Immunol Cell Biol
Date: 2014-07-01
- Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Journal: Br J Cancer
Date: 2014-05-11
- Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)
Journal: Breast
Date: 2014-04-11
- Acute exercise leads to regulation of telomere-associated genes and microRNA expression in immune cells.
Journal: PLoS One
Date: 2014-04-01
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Journal: Lancet
Date: 2013-05-11
- Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
Journal: Haematologica
Date: 2012-02-11
- Breast-cancer adjuvant therapy with zoledronic acid.
Journal: The New England Journal of Medicine
Date: 2011-10-11
- Adjuvant trastuzumab in HER2-positive breast cancer.
Journal: The New England Journal of Medicine
Date: 2011-10-11
- A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.
Journal: Cancer Genet
Date: 2011-04-11
- Murine hepatitis virus RNA, complete genome, strain: MHV-MI
Journal: DNA Data Bank of Japan
Date: 2010-03-12
- Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia.
Journal: Br J Haematol
Date: 2007-11-11
- The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.
Journal: Blood
Date: 2006-02-11
- The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report.
Journal: American Journal of Hematology
Date: 2005-06-11
- Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab.
Journal: Clin Oncol
Date: 2005-06-11
- A human complement-fixing monoclonal anti-human lymphocyte antibody of rat origin.
Journal: Immunology and Cell Biology
Date: 2005-06-11
- Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.
Journal: American Journal of Hematology
Date: 2003-11-11
- A time to kill: viral manipulation of the cell death program.
Journal: Journal of General Virology
Date: 2002-07-01
- Glycogen storage disease.
Journal: Semin Hematol
Date: 2002-04-01
- Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia.
Journal: Blood
Date: 2000-10-11
- Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.
Journal: Blood
Date: 2000-07-11
- Novel endogenous type D retroviral particles expressed at high levels in a SCID mouse thymic lymphoma.
Journal: Journal of Virology
Date: 1999-06-11
- Perivascular T cells express the pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions.
Journal: Scand J Immunol
Date: 1997-03-11
- Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle.
Journal: Muscle Nerve
Date: 1996-10-11
- EWS/FLI-1 fusion transcript detection and MIC2 immunohistochemical staining in the diagnosis of Ewing’s sarcoma.
Journal: Pediatr Pathol Lab Med
Date: 1996-05-11
- Cytogenetic and DNA analysis of two neuroectodermal tumors without a simple t(11;22).
Journal: Cancer Genet Cytogenet
Date: 1995-08-11
- Soluble antigen can cause enhanced apoptosis of germinal-centre B cells.
Journal: Nature
Date: 1995-05-11
- bcl-2 transgene expression can protect neurons against developmental and induced cell death.
Journal: Proc Natl Acad Sci U S A
Date: 1995-05-11
- Viable bone marrow stromal cells are required for the in vitro survival of B-cell precursor acute lymphoblastic leukemic cells.
Journal: Leukemia Research
Date: 1995-02-11
- Flow cytometric analysis of intercellular adhesion between B-cell precursor acute lymphoblastic leukemic cells and bone marrow stromal cells.
Journal: Leukemia
Date: 1995-01-11
- Kiz-1, a protein with LIM zinc finger and kinase domains, is expressed mainly in neurons
Journal: Cell Growth Differentiation
Date: 1994-11-11
- The role of cytokines in the pathogenesis of Langerhans cell histiocytosis.
Journal: Br J Cancer Suppl
Date: 1994-09-11
- The biology of erythropoietin and its role in the anaemia of prematurity
Journal: Journal of Paediatric Child Health
Date: 1994-08-11
- Human bone marrow stromal cell contact and soluble factors have different effects on the survival and proliferation of paediatric B-lineage acute lymphoblastic leukaemic blasts.
Journal: Leuk Res
Date: 1994-05-11
- Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group
Journal: Journal of Clinical Oncology
Date: 1994-03-11
- Measurement of the growth parameters of precursor B-acute lymphoblastic leukaemic cells in co-culture with bone marrow stromal cells; detection of two cd10 positive populations with different proliferative capacities and survival.
Journal: Leuk Res
Date: 1994-01-11
- A novel approach to the measurement of different in vitro leukaemic cell growth parameters: the use of PKH GL fluorescent probes.
Journal: Leuk Res
Date: 1993-10-11
- A method for the treatment of tumours and sarcomas
Journal: International Patent PL 0164/91
Date: 1993-08-12
- Characterization of stroma-adherent colony-forming cells: a clonogenic assay for early hemopoietic cells?
Journal: Exp Hematol
Date: 1993-03-11
- SCL gene in human tumors.
Journal: Leukemia
Date: 1992-07-11
- Characterization of interleukin-3 and granulocyte-macrophage receptors on normal human hemopoietic cells
Journal: Molecular Biology of Hematopoiesis
Date: 1990-12-12
- Proliferative properties of unfractionated, purified, and single cell human progenitor populations stimulated by recombinant human interleukin-3
Journal: Blood
Date: 1990-01-11
- Cellular and humoral interactions in haemopoiesis
Journal: University of Melbourne
Date: 1988-12-12
- Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.
Journal: Blood
Date: 1988-12-11
- Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay
Journal: Blood
Date: 1988-11-11
- Enhancement of in vitro beta-thalassemic and normal hematopoiesis by a noncytotoxic monoclonal antibody, 9.1C3: evidence for negative regulation of hematopoiesis by monocytes and natural killer cells.
Journal: Blood
Date: 1988-10-11
- Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy.
Journal: Behring Inst Mitt
Date: 1988-08-11
- Activated killer cell lymphoma: an erythrophagocytic syndrome simulating histiocytic medullary histiocytosis.
Journal: Pathology
Date: 1988-07-11
- Clonal proliferation in vitro of individual murine and human hemopoietic cells after fluorescence-activated cell sorting.
Journal: Exp Hematol
Date: 1988-06-11
- Evidence for interactions between monocytes and natural killer cells in the regulation of in vitro hemopoiesis
Journal: Journal of Immunology
Date: 1988-04-11
- Fractionation of subsets of BFU-E from normal human bone marrow: responsiveness to erythropoietin, human placental-conditioned medium, or granulocyte-macrophage colony-stimulating factor.
Journal: Blood
Date: 1988-03-11
- Fractionation of normal and beta-thalassemic human hemopoietic progenitor cells by immunomagnetic beads.
Journal: Exp Hematol
Date: 1987-12-11
- Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage.
Journal: Cell
Date: 1987-11-11
- Studies by radioiodination of normal adult, fetal and leukemic cell membranes.
Journal: Exp Hematol
Date: 1987-09-11
- Osmotic fragility of leukaemic and normal lymphocytes
Journal: Pathology
Date: 1987-04-11
Associate Professor Prashanth Prithviraj
MBBS MSc MPH FRACP PhD
Honorary Senior Research Fellow
Dr Prashanth Prithviraj, who recently completed PhD in cancer biology at The Austin Hospital (Oliva Newton-John Cancer Research Institute) joined the institute in September 2017 as Senior Research Fellow. After earning his medical degree, Prashanth pursued Medical Oncology training at Calvary Mater Newcastle Hospital, he furthered his education and completed training with a Fellowship in Medical Oncology at The Austin Hospital in Melbourne. Prashanth has extensive research experience and his other qualifications apart from FRACP include Masters of Science (Biotechnology) from University of Western Sydney and Master of Public Health (Epidemiology and Statistics) from the University of Newcastle. Prashanth has presented at major national and international meetings, and authored publications in prominent cancer related peer reviewed journals. He has a special interest in transitional research and immunotherapy, and is a lead investigator in a number of clinical trials, and also is involved in development and conduct of clinical trials. His research goals are to develop innovative models to establish EMT mechanism as an important biomarker for cancer progression, resistance to therapy and as a biomarker of responsiveness to immune therapy, with the aim of developing/designing EMT-based therapies in cancer.
Publications
- Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma
Journal: Cancers
Date: 2026-07-21
- Recent Developments in Single-Cell Transcriptomics
Journal: Springer Nature
Date: 2026-05-25
- Synthetic Biology in Precision Medicine and Nanotechnology
Journal: Springer Nature
Date: 2026-05-25
- Synthetic Biology for Cancer Stem Cells
Journal: Springer Nature
Date: 2026-05-25
- Nanotechnology in the Generation and Analysis of Single Cells
Journal: Springer Nature
Date: 2026-05-25
- Advances in CRISPR/Cas systems-based cell and gene therapy
Journal: Epub
Date: 2024-08-11
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: 2022-10-01
- Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
Journal: Front Med (Lausaane)
Date: 2022-06-01
- CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
Journal: International Journal of Molecular Sciences
Date: 2022-01-11
- Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
Journal: Journal of Clinical Medicine
Date: 2021-05-01
- Determinants of Resistance to VEGF-TKI and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: 2021-04-08
- Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
Journal: Scientific Reports
Date: 2020-08-08
- Combined inhibition of TGF-β1-induced EMT and PD-L1 silencing re-sensitizes hepatocellular carcinoma to Sorafenib treatment.
Journal: Journal of Clinical Medicine
Date: 2020-05-01
- Epithelial-to-mesenchymal transition as a robust biomarker and a novel strategy to enhance response to immune checkpoint blockade and targeted therapy in patients with metastatic renal cell carcinoma
Journal: Asia-pacific Journal of Clinical Oncology
Date: 2018-11-12
- Immune checkpoint inhibitors and tumor mutation burden as predictive biomarkers in hepatocellular carcinoma
Journal: Journal of Gastroenterology and Hepatology
Date: 2018-09-11
- Exosome-based liquid biopsy in the management of hepatocellular carcinoma
Journal: Hepatoma Res
Date: 2018-08-11
- Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Journal: Frontier Oncology
Date: 2018-07-11
- Prognostic Impact of Immune Checkpoint Inhibitor Expression and Its Association with Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
Journal: Hepatology
Date: 2018-01-12
- PAPP-A is a marker of aggressive breast cancer and promotes cancer progression in-vitro
Journal: Annals of Oncology
Date: 2017-11-06
- abs# 11 Patterns of Use of Adjuvant Therapy in Patients with Stage 1 Nsgct
Journal: Asia-pacific Journal of Clinical Oncology
Date: 2016-12-08
- Identifying and targeting determinants of melanoma cellular invasion
Journal: Oncotarget
Date: 2016-07-08
- Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Journal: British Journal of Cancer
Date: 2016-05-08
- Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells
Journal: BMC cancer
Date: 2016-02-08
- Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
Journal: Journal for Immunotherapy of Cancer
Date: 2015-11-08
- Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.
Journal: Oncotarget
Date: 2015-06-11
- Embryonic chicken transplantation is a promising model for studying the invasive behavior of melanoma cells
Journal: Cellular and Phenotypic Plasticity in Cancer
Date: 2015-02-08
- Thrombospondin-1 promotes an aggressive phenotype through epithelial-to mesenchymal transition in human melanoma
Journal: Oncotarget
Date: 2014-07-08
- Effect of pregnant sera and a pregnancy-associated metalloproteinase (PAPP-A) on melanoma in vitro and in vivo: Insights into melanoma progression during pregnancy and potential new therapeutic targets.
Journal: Journal of Clinical Oncology
Date: 2014-07-08
- Patterns of use of adjuvant therapy in patients with stage 1 NSGCT
Journal: Bju International
Date: 2013-07-08
- Mechanism of IGF induced epithelial-to-mesenchymal transition (EMT) in melanoma progression
Journal: Asia-Pacific Journal of Clinical Oncology
Date: 2012-11-12
Professor Nuzhat Ahmed
BSc Hons (DU), MSc (KUL), PhD (ANU
John Turner Professorial Fellow
Nuzhat joined the Institute in 2015 and is the John Turner Professorial Fellow. She holds an adjunct professorial position with the Federation University, Ballarat which strengthens links between the Institute and the University. Professor Ahmed is an experienced cell and molecular biologist and brings a wealth of experience to Institute, particularly in cancer biology. She has a long-standing interest in understanding the molecular mechanisms of ovarian cancer spread. She did her postdoctoral research training in Malaghan Institute of Medical Research, New Zealand, University of Newcastle, Australia, Kanagawa Cancer Centre, Japan and BC Cancer Agency, University of British Columbia in Canada. From 2002-2014 Nuzhat led the Cancer Metastasis Group in Women’s Cancer Research Centre, Royal Women’s Hospital, Melbourne. Her significant contribution has been in establishing novel interactions of cell adhesion molecules with the signalling pathways in cancer, identifying early stage biomarkers for ovarian cancer screening and understanding the mechanisms of chemoresistance in ovarian cancer patients. These studies have led to several international patents, competitive international and national grants and publications (>80) in reputable cancer journals. Nuzhat has a long-standing interest in understanding the immune cell irregularities in ovarian cancer patients.
Publications
- Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion
Journal: Journal of Biomedical Science
Date: 2026-06-26
- Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion
Journal: J Biomed Sci
Date: 2026-06-21
- Enhanced Expression of Mitochondrial Magmas Protein in Ovarian Carcinomas: Magmas Inhibition Facilitates Antitumour Effects, Signifying a Novel Approach for Ovarian Cancer Treatment
Journal: Cells
Date: 2025-04-01
- Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets
Journal: Cancers (Basel)
Date: 2024-12-12
- A three-stage developmental pathway for human Vγ9Vδ2 T cells within the postnatal thymus
Journal: Sci Immunol
Date: 2023-07-12
- In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.
Journal: Cancers
Date: 2023-05-01
- Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
Journal: Cancer Cell International
Date: 2023-02-01
- Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism
Journal: Journal of Translational Medicine
Date: 2022-12-11
- Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
Journal: Front Med (Lausaane)
Date: 2022-06-01
- Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment
Journal: Frontiers in Oncology
Date: 2022-01-11
- The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence
Journal: Cell Commun Signal
Date: 2021-05-11
- Determinants of Resistance to VEGF-TKI and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma
Journal: Journal of Experimental & Clinical Cancer Research
Date: 2021-04-08
- TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
Journal: BMC Cancer
Date: 2020-10-08
- In Vitro and In Vivo Toxicity and Biodistribution of Paclitaxel-Loaded Cubosomes as a Drug Delivery Nanocarrier: A Case Study Using an A431 Skin Cancer Xenograft Model
Journal: ACS Applied Bio Materials
Date: 2020-06-08
- Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods
Journal: Cells
Date: 2020-03-08
- The Potential Role of Interleukin-11 in Epithelial Ovarian Cancer
Journal: Journal of Cancer Science and Clinical Therapeutics
Date: 2019-02-08
- Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer.
Journal: Cancers
Date: 2019-02-08
- Epithelial-to-mesenchymal transition as a robust biomarker and a novel strategy to enhance response to immune checkpoint blockade and targeted therapy in patients with metastatic renal cell carcinoma
Journal: Asia-pacific Journal of Clinical Oncology
Date: 2018-11-12
- Tumour Microenvironment and Metabolic Plasticity in Cancer and Cancer Stem Cells: Perspectives on Metabolic and Immune Regulatory Signatures in Chemoresistant Ovarian Cancer Stem Cells.
Journal: Seminars in Cancer Biology
Date: 2018-07-08
- Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer
Journal: ACS Applied Materials & Interfaces
Date: 2018-07-01
- Momelotinib reduces cancer stem cell load leading to a decreased tumor burden and a prolonged disease-free remission period in a mouse model of human ovarian cancer
Journal: Oncotarget
Date: 2018-03-12
- Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
Journal: Oncotarget
Date: 2018-03-01
- The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.
Journal: International Journal of Molecular Sciences Review
Date: 2018-01-01
- Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays- Chapter 20.
Journal: Methods Molecular Biology, Vol. 1619, Serum/Plasma Proteomics, 978-1-4939-7056-8
Date: 2017-12-08
- Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling
Journal: Scientific Reports
Date: 2017-04-12
- Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer
Journal: Advances in Current Drug Targets, Vol 3, Bentham Science Publishers
Date: 2016-12-12
- Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.
Journal: Scientific Reports
Date: 2016-07-08
- Molecular pathways regulating epidermal growth factor-induced epithelio-mesenchymal transition in human ovarian surface epithelium.
Journal: American Journal of Physiology: Cell Physiology
Date: 2016-07-01
- Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells
Journal: Scientific Reports
Date: 2016-07-01
- A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
Journal: Molecular Cancer
Date: 2015-08-01
- Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.
Journal: Carcinogenesis
Date: 2015-06-01
- Enhanced activation of STAT3 in ascites-derived recurrent ovarian tumors: inhibition of cisplatin-induced STAT3 activation reduced tumorigenicity of ovarian cancer by a loss of cancer stem cell-like characteristics.
Journal: Journal of Cancer Stem Cell Research
Date: 2015-01-01
- Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFkB-mediated induction of MMP2.
Journal: Cancer Letters
Date: 2014-11-11
- Distinct molecular signature of recurrent ovarian tumor cells isolated from the ascites of advanced-stage serous ovarian cancer patients.
Journal: Journal of Cancer Stem Cell Research
Date: 2014-10-01
- Targeted disruption of JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden.
Journal: Frontiers in Oncology
Date: 2014-05-01
- Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden
Journal: BMC Cancer
Date: 2014-05-01
- Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer
Journal: Br J Cancer
Date: 2013-11-01
- Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research
Journal: Frontiers in Oncology
Date: 2013-09-01
- Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets
Journal: Mol Aspects Med
Date: 2013-06-12
- Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets.
Journal: Molecular Aspects of Medicine
Date: 2013-06-01
- Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Journal: Molecular Cancer
Date: 2013-03-11
- Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance
Journal: Journal of Cellular Biochemistry
Date: 2013-01-11
- Investigation of human cationic antimicrobial protein-18 (hCAP-18), lactoferrin and CD163 as potential biomarkers for ovarian cancer
Journal: Journal of Ovarian Research
Date: 2013-01-01
- Attributes of Oct4 in stem cell biology: Perspectives on cancer stem cells of the ovary
Journal: Journal of Ovarian Research
Date: 2012-11-01
- Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemo resistant ovarian tumors
Journal: PloS One
Date: 2012-10-11
- Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor micro-environment
Journal: Cancer Microenvironment
Date: 2012-04-01
- Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profiles
Journal: Journal of Cellular Biochemistry
Date: 2011-10-01
- Effect of silencing neutrophil gelatinase-associated lipocalin in ovarian cancer cells on epithelio-mesenchymal transition.
Journal: Journal of Molecular Biomarkers and Diagnosis
Date: 2011-08-01
- 2D-PAGE of Ovarian Cancer: Analysis of soluble and insoluble fractions using narrow pH ranges
Journal: Biochemical and Biophysical Research Communication
Date: 2011-02-01
- Neuronal transcription factor Brn-3a is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer.
Journal: Journal of Ovarian Research
Date: 2010-07-01
- Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer
Journal: Curr Cancer Drug Targets
Date: 2010-05-01
- Multicellular spheroids in ovarian cancer metastases: Biology and pathology.
Journal: Gynecology Oncology
Date: 2009-04-01
- Cross talk of signals between EGFR and IL-6R via JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Journal: British Journal of Cancer
Date: 2008-12-01
- Epidermal growth factor induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of a6b1 integrin.
Journal: International Journal of Biochemistry Cell Biology
Date: 2008-12-01
- Immunohistochemical perspective of PPARb and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours
Journal: British Journal of Cancer
Date: 2008-05-01
- Epithelial-Mesenchymal interconversions in normal ovarian epithelium and ovarian carcinomas: an exception to the norm
Journal: Journal of Cellular Physiology
Date: 2007-12-01
- a2b1 integrin affects metastatic ability of ovarian carcinoma spheroids by supporting disaggregation and proteolysis.
Journal: Journal of Carcinogenesis
Date: 2007-06-01
- Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition.
Journal: International Journal of Cancer
Date: 2007-02-01
- Immunohistochemistry and in situ hybridization of human carcinomas
Journal: Molecular genetics Volume 4
Date: 2006-01-01
- Proteomics tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Journal: Proteomics
Date: 2005-11-01
- Translational Proteomics: Developing a predictive capacity.
Journal: Placenta
Date: 2005-11-01
- Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix micro-environment.
Journal: Clin Expt Metastasis
Date: 2005-06-01
- Ascites induces modulation of a6 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Journal: British Journal of Cancer
Date: 2005-04-01
- Strategies for revealing lower abundance proteins in two-dimensional protein maps.
Journal: Journal of Chromatography
Date: 2005-03-01
- Enhanced expression of peroxisome proliferator receptor g expression in ovarian carcinoma.
Journal: British Journal of Cancer
Date: 2005-01-01
- Proteomics based identification of hatoglobin-1 precursor as a novel circulating biomarker for ovarian cancer.
Journal: British Journal of Cancer
Date: 2004-06-01
- Cell-free 59 kDa Immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma.
Journal: Clinical Cancer Research
Date: 2004-04-01
- Expression and localization of avb6 integrin in extraplacental fetal membranes: possible role in human parturition.
Journal: Molecular Human Reproduction
Date: 2004-01-01
- Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid.
Journal: Journal of Pathology
Date: 2003-10-01
- An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum
Journal: Proteomics
Date: 2003-10-01
- Down regulation of urokinase plasminogen activator expression inhibits Erk signaling with concomitant suppression of matrix metalloprotease-9 (MMP-9) due to loss of uPAR-b1 integrin complex in colon cancer.
Journal: British Journal of Cancer
Date: 2003-07-01
- Proteomic profiling of proteins associated with urokinase plasminogen activator receptor (uPAR) in colon cancer cells using an antisense approach
Journal: Proteomics
Date: 2003-03-01
- avb6 Integrin- A marker for the malignant potential of epithelial ovarian cancer
Journal: J Hist. Cytochem
Date: 2002-10-01
- Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the b6 integrin subunit.
Journal: International Journal of Cancer
Date: 2002-04-01
- Direct integrin avb6-Erk binding: implications for tumour growth
Journal: Oncogene
Date: 2002-02-01
- Overexpression of avb6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.
Journal: Carcinogenesis
Date: 2002-02-01
- Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer
Journal: J Cell Biochem
Date: 2002-01-01
- The avb6 integrin regulates its own expression with cell crowding: implications for tumor progression.
Journal: nt. J. Cancer
Date: 2001-04-01
- New insights into mammalian sugar transport and its regulation at the plasma membrane
Journal: NZ BioScience
Date: 1999-12-12
- Ceramides that mediate apoptosis reduce glucose uptake and transporter affinity for glucose in human leukaemic cell lines but not in neutrophils
Journal: Pharmacology and Toxicology
Date: 1999-09-11
- Distinct regulation of glucose transport by Interleukin-3 and oncogenes in a murine bone marrow derived cell line
Journal: Biochemical Pharmacology
Date: 1999-09-01
- IL-3 induces apoptosis: Differential effect of IL-3 on the survival and growth response of parental and oncogene-transfected cells
Journal: Apoptosis
Date: 1999-04-08
- N -glycosylation of glucose transporter-1 (Glut-1) is associated with increased transporter affinity for glucose in human leukemic cells
Journal: Leukemia Research
Date: 1999-04-01
- Telomerase activity in a specific cell subset coexpressing integrin b1/EGFR but not p75NGFR/bcl2 in normal human epithelial cell.
Journal: Oncogene
Date: 1998-08-01
- Acute regulation of glucose transport after activation of human peripheral blood neutrophils by phorbol myristate acetate, fMLP and granulocyte-macrophage colony-stimulating factor.
Journal: Blood
Date: 1998-01-11
- Transforming oncogenes regulate glucose transport by increasing transporter affinity for glucose: Contrasting effects of oncogenes and heat stress in a murine bone marrow-derived cell line.
Journal: Life Sciences
Date: 1998-01-08
- Acute regulation of glucose transport in a monocyte-macrophage cell line: Glut-3 activity for glucose is enhanced during the respiratory burst.
Journal: Biochem J
Date: 1997-10-11
- The hemopoietic growth factor, interleukin-3, promotes glucose transport by increasing the specific activity and maintaining the affinity for glucose of plasma membrane glucose transporters in a bone marrow-derived cell line: Possible involvement of phosphorylation in the activation of transporters.
Journal: J Biol. Chem.
Date: 1997-07-01
- Regulation of glucose transport by interleukin-3 in growth factor-dependent and oncogene-transformed bone marrow derived cell lines.
Journal: Leukemia Research
Date: 1997-07-01
- Interaction of reactive nitrogen and oxygen intermediates in HL60 and dimethyl sulphoxide-differentiated HL60 cells
Journal: Leukemia Research
Date: 1997-03-01
- Biochemical effect of three different inhibitors of purine/pyrimidine metabolism on differentiation in HL60 cells.
Journal: Leukemia Research
Date: 1995-04-11
- Purine metabolism in promyelocytic HL60 and dimethyl sulphoxide-differentiated HL60 cells.
Journal: Leukemia Research
Date: 1994-06-01
- Glycolytic, glutaminolytic and pentose-phosphate pathways in promyelocytic HL60 and DMSO-differentiated HL60 cells.
Journal: Biochem. & Mol. Biol. Int
Date: 1993-04-01
- The impact of low dose carcinogens and environmental disrupters on tissue invasion and metastasis.
Journal: Carcinogenesis
Date: 1991-02-01
- The Human promyelocytic HL60 cell line: A model of myeloid cell differentiation using dimethylsulphoxide, phorbol ester and butyrate.
Journal: Biochem. Int
Date: 1991-02-01
- Oral Cholera vaccines containing b-subunit-killed whole cells and whole cells only. Cross reacting antigens of the members of family Vibrionaceae and the vaccines.
Journal: Vaccine
Date: 1989-04-01
Associate Professor Aparna Jayachandran
BSc, MSc, PhD
Senior Research Fellow
Dr Jayachandran is an internationally recognised cancer researcher, with her most recent appointment prior the Institute was as the Head of the Liver Cancer Unit at the Gallipoli Medical Research Institute at the University of Queensland. She has also held appointments at the Liebig University, Germany and Mount Sinai School of Medicine, New York, University of Melbourne, Latrobe University, and the Olivia Newton John Cancer Research Institute. Her background and expertise in cancer biology, epithelial-to-mesenchymal transition, cancer stem cells, and organ fibrosis is an asset to the team.
Publications
- Juxtamembrane Mimic Peptide Loaded Injectable Sodium Alginate/Bioglass Bioactive Hydrogel for Suppressing Tumor Recurrence in Post-Breast-Conserving-Surgery Treatment
Journal: ACS Appl Bio Mater
Date: 2026-08-21
- Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma
Journal: Cancers
Date: 2026-07-21
- Synthetic Biology in Precision Medicine and Nanotechnology
Journal: Springer Nature
Date: 2026-05-25
- Synthetic Biology for Cancer Stem Cells
Journal: Springer Nature
Date: 2026-05-25
- Recent Developments in Single-Cell Transcriptomics
Journal: Springer Nature
Date: 2026-05-25
- Nanotechnology in the Generation and Analysis of Single Cells
Journal: Springer Nature
Date: 2026-05-25
- Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo
Journal: Theranostics
Date: 2026-01-08
- Ubiquitin-Specific Protease 43 Promotes Degradation of Phenylalanine Hydroxylase in Mammalian Cells
Journal: Molecular Biology
Date: 2025-12-12
- Pregnancy-associated plasma protein-A drives melanoma metastasis and immune evasion via IGF signaling
Journal: Preprint
Date: 2025-09-12
- Microgel-based bioink for extrusion-based 3D bioprinting and its applications in tissue engineering
Journal: Bioact Mater
Date: 2025-06-04
- Impact of Ligand Concentration on the Properties of Nucleic-Acid-Encapsulated MOFs and Inflammation Modulation in Prostate Cancer Cells
Journal: ACS Appl Bio Mater
Date: 2024-11-01
- Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
Journal: Cells
Date: 2024-10-01
- Advances in applications of the CRISPR/Cas9 system for respiratory diseases
Journal: Prog Mol Biol Transl Sci
Date: 2024-08-12
- Recent progress in CRISPR/Cas9 system for eye disorders
Journal: Prog Mol Biol Transl Sci
Date: 2024-08-11
- Advances in CRISPR/Cas systems-based cell and gene therapy
Journal: Epub
Date: 2024-08-11
- The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits
Journal: Journal of Biomedical Science
Date: 2024-02-01
- In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.
Journal: Cancers
Date: 2023-05-01
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: 2022-10-01
- CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
Journal: International Journal of Molecular Sciences
Date: 2022-01-11
- Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
Journal: Curr Oncol
Date: 2021-06-01
- Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
Journal: Journal of Clinical Medicine
Date: 2021-05-01
- Combination targeting of epithelial-to-mesenchymal transition and immune checkpoint molecules resensitizes hepatocellular carcinoma to sorafenib treatment
Journal: Journal of Gastroenterology and Hepatology
Date: 2021-04-11
- Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Journal: International Journal of Medical Sciences
Date: 2021-03-11
- Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
Journal: Scientific Reports
Date: 2020-08-08
- Combined inhibition of TGF-β1-induced EMT and PD-L1 silencing re-sensitizes hepatocellular carcinoma to Sorafenib treatment.
Journal: Journal of Clinical Medicine
Date: 2020-05-01
- TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma.
Journal: Molecular Medicine Reports
Date: 2020-04-11
- Association between hereditary hemochromatosis and hepatocellular carcinoma: a comprehensive review
Journal: Hepatoma Res.
Date: 2020-03-11
- Immune checkpoint blockade therapies for HCC: current status and future implications
Journal: Hepatoma Res
Date: 2019-09-11
- Enrichment of multiple immune checkpoints in cholangiocarcinoma cancer stem cells
Journal: Journal of Gastroenterology and Hepatology
Date: 2019-01-12
- Attenuation of receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain like pseudokinase (MLKL) blocks the TRIF-RIPK3-MLKL-driven necroptotic cell death in steatotic hepatocytes undergoing ischemic injury
Journal: Journal of Gastroenterology and Hepatology
Date: 2019-01-12
- Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma.
Journal: Expert Opin Investig Drugs.
Date: 2019-01-11
- TNF-α promotes epithelial-to-mesenchymal transition and expression of immune checkpoint molecules in hepatocellular carcinoma
Journal: Journal of Gastroenterology and Hepatology
Date: 2019-01-11
- Epithelial-to-mesenchymal transition as a robust biomarker and a novel strategy to enhance response to immune checkpoint blockade and targeted therapy in patients with metastatic renal cell carcinoma
Journal: Asia-pacific Journal of Clinical Oncology
Date: 2018-11-12
- Necroptosis Contributes to Cell Death of Steatotic Hepatocytes Following Ischaemic Injury
Journal: Hepatology
Date: 2018-10-12
- H-Ferritin and iron activate inflammatory pathways in adipocytes
Journal: Journal of Gastroenterology and Hepatology
Date: 2018-09-12
- Immune checkpoint inhibitors and tumor mutation burden as predictive biomarkers in hepatocellular carcinoma
Journal: Journal of Gastroenterology and Hepatology
Date: 2018-09-11
- Exosome-based liquid biopsy in the management of hepatocellular carcinoma
Journal: Hepatoma Res
Date: 2018-08-11
- Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Journal: Frontier Oncology
Date: 2018-07-11
- Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma.
Journal: Gene Ther
Date: 2018-04-11
- Prognostic Impact of Immune Checkpoint Inhibitor Expression and Its Association with Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
Journal: Hepatology
Date: 2018-01-12
- Evaluation of tumor specific promoters for transcriptional targeting of hepatocellular carcinoma
Journal: Journal of Gene Medicine
Date: 2018-01-12
- Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma.
Journal: Drug Delivery
Date: 2017-11-11
- PAPP-A is a marker of aggressive breast cancer and promotes cancer progression in-vitro
Journal: Annals of Oncology
Date: 2017-11-06
- Gene therapy targeting of choroidal disease and AAV transcytosis through the outer blood retina barrier epithelium
Journal: Acta Ophthalmologica
Date: 2017-09-12
- Genetic evidence for the role of ultraviolet radiation in the pathogenesis of uveal melanoma
Journal: Acta Ophthalmologica
Date: 2017-09-12
- Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity.
Journal: World Journal of Stem Cells
Date: 2017-09-11
- Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.
Journal: Oncotarget
Date: 2017-05-06
- Two-photon dual imaging platform for in vivo monitoring cellular oxidative stress in liver injury.
Journal: Sciencfic Reports
Date: 2017-03-06
- Characterizing and combating the immune modulatory and epithelial-to-mesenchymal plasticity properties of hepatocellular carcinoma-derived cancer stem cells
Journal: CQUniversity
Date: 2017-01-12
- Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Journal: Current Cancer Drug targets
Date: 2017-01-11
- In vivo quantitative visualization of hypochlorous acid in the liver using a novel selective two-photon fluorescent probe
Journal: SPIE BioPhotonics Australasia
Date: 2016-11-12
- Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma.
Journal: Journal Hematology Oncology
Date: 2016-08-11
- Identifying and targeting determinants of melanoma cellular invasion
Journal: Oncotarget
Date: 2016-07-08
- Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Journal: Molecular Cancer Therapeutics
Date: 2016-06-06
- Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells
Journal: BMC cancer
Date: 2016-02-08
- Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.
Journal: Oncotarget
Date: 2015-06-11
- Embryonic chicken transplantation is a promising model for studying the invasive behavior of melanoma cells
Journal: Cellular and Phenotypic Plasticity in Cancer
Date: 2015-02-08
- Epithelial-to-mesenchymal transition as a potential target for antineoplastic therapies.
Journal: J Cancer Clin Trials
Date: 2015-01-06
- Effects of epithelial-to-mesenchymal transition on T cell targeting of melanoma cells
Journal: Front Oncol.
Date: 2014-12-06
- Thrombospondin 1 promotes anin vitroandin vivoinvasive phenotype through epithelial-to-mesenchymal transition in human melanoma
Journal: Pigment Cell & Melanoma Research
Date: 2014-11-12
- Thrombospondin-1 is a targetable marker of invasive, mesenchymal-like melanoma cells
Journal: Cancer Research
Date: 2014-10-06
- Effect of pregnant sera and a pregnancy-associated metalloproteinase (PAPP-A) on melanoma in vitro and in vivo: Insights into melanoma progression during pregnancy and potential new therapeutic targets.
Journal: Journal of Clinical Oncology
Date: 2014-07-08
- Thrombospondin-1 promotes an aggressive phenotype through epithelial-to mesenchymal transition in human melanoma
Journal: Oncotarget
Date: 2014-07-08
- FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.
Journal: Oncotarget
Date: 2014-01-06
- Slow-Cycling Melanoma Cells are Resistant to Therapy and Exhibit a Targetable EMT-Related Expression Profile
Journal: Journal der Deutschen Dermatologischen Gesellschaft
Date: 2013-07-12
- Metalloproteinase pregnancy associated plasma protein-A (PAPP-A) promotes melanoma progression in vitro
Journal: Asia-Pacific Journal of Clinical Oncology
Date: 2013-07-12
- Mechanism of IGF induced epithelial-to-mesenchymal transition (EMT) in melanoma progression
Journal: Asia-Pacific Journal of Clinical Oncology
Date: 2012-11-12
- Role of cytokine-induced plasticity in melanoma on invasive, therapy-resistant cells that express EMT-related genes and pathways
Journal: Journal of Clinical Oncology
Date: 2012-05-12
- SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis
Journal: Thorax
Date: 2009-10-12
- Rapid loss of the alveolar epithelial cell phenotype during primary culture in a matrix-independent fashion
Journal: Pneumologie
Date: 2008-12-12
- Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis.
Journal: FASAB Journal
Date: 2008-06-06
- Protein profiling of cultured primary alveolar epithelial type II cells reveals a rapid loss of the alveolar phenotype
Journal: Pneumologie
Date: 2007-12-12
- SNAI transcription factors in epithelial-to-mesenchymal transition: Comparative analysis of experimental and idiopathic pulmonary fibrosis
Journal: Pneumologie
Date: 2007-12-12
- Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice.
Journal: American Journal of Pathology
Date: 2007-09-06
- Snail and Slug are Key Mediators of TGF-beta-induced Epithelial-to-Mesenchymal Transition in Lung Fibrosis
Journal: Pneumologie
Date: 2007-01-12
- Snail and slug as central mediators of the TGF-beta-induced epithelial-to-mesenchymal transition (EMT) in pulmonary fibrosis
Journal: Medizinische Klinik
Date: 2006-04-12
Dr Rodney Luwor
BSc PhD
Senior Research Fellow
Dr Luwor joined the Institute in 2021, bringing with him almost two decades experience in using human cancer models and human patient samples to investigate the genetic and molecular alterations associated with cancer. Further to this Dr Luwor has expertise in developing molecular therapeutics for inhibition of tumour growth and progression. In particular, Dr Luwor has performed pre-clinical, therapeutic evaluation of several agents designed to block tumour growth. More recently, Dr Luwor has expanded his research interests to explore tumour resistance to both molecular targeted therapy and standard chemotherapy.
Publications
- Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma
Journal: Biology (Basel)
Date: 2026-09-02
- Juxtamembrane Mimic Peptide Loaded Injectable Sodium Alginate/Bioglass Bioactive Hydrogel for Suppressing Tumor Recurrence in Post-Breast-Conserving-Surgery Treatment
Journal: ACS Appl Bio Mater
Date: 2026-08-21
- Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment
Journal: Immunol Cell Biol
Date: 2026-07-21
- The Signaling Networks of TIM-3, TGF-β and STING in Glioblastoma
Journal: Cells
Date: 2026-05-29
- Effect of methanolic extract of Salix babylonica on biochemical parameters and gene expression in streptozotocin induced diabetic rat model
Journal: Fitoterapia
Date: 2026-04-08
- Methanol extract of Chenopodium murale L. attenuated TNF-α-mediated oxidative stress and inflammation in murine models
Journal: Inflammopharmacology
Date: 2026-03-13
- Correlation of Galectin Family Expression with Glioblastoma Progression and Survival
Journal: Int J Mol Sci
Date: 2025-12-01
- Mechanistic insight into inflammatory and oxidative stress ameliorating attributes of Atriplex crassifolia 70% ethanol extract against complete Freund’s adjuvant-induced arthritis
Journal: Inflammopharmacology
Date: 2025-10-01
- Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell lines
Journal: Commun Biol
Date: 2025-06-11
- Microgel-based bioink for extrusion-based 3D bioprinting and its applications in tissue engineering
Journal: Bioact Mater
Date: 2025-06-04
- Enhanced Expression of Mitochondrial Magmas Protein in Ovarian Carcinomas: Magmas Inhibition Facilitates Antitumour Effects, Signifying a Novel Approach for Ovarian Cancer Treatment
Journal: Cells
Date: 2025-04-01
- Immunomodulatory properties of a methanolic extract of Ficus lyrata mitigate inflammation in Complete Freund’s Adjuvant-induced arthritis
Journal: Inflammopharmacology
Date: 2025-03-11
- The Role of TIM-3 in Glioblastoma Progression
Journal: Cells
Date: 2025-02-01
- Systemic brain dissemination of glioblastoma requires transdifferentiation into endothelial-like cells via TGF-β-ALK1-Smad1/5 signaling
Journal: Neoplasia
Date: 2025-02-01
- Gold(I) complexes of the type [AuL{kappaC-2-C(6)H(4)P(S)Ph(2)}] [L = PTA, PPh(3), PPh(2)(C(6)H(4)-3-SO(3)Na) and PPh(2)(2-py)]: Synthesis, characterisation, crystal structures, and In Vitro and In Vivo anticancer properties.
Journal: Eur J Med Chem
Date: 2025-01-11
- Transforming growth factor-β in tumor microenvironment: Understanding its impact on monocytes and macrophages for its targeting.
Journal: Int Rev Immunol
Date: 2024-10-01
- Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
Journal: Cells
Date: 2024-10-01
- hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560
Journal: PLoS One
Date: 2024-09-01
- Advances in CRISPR/Cas systems-based cell and gene therapy
Journal: Epub
Date: 2024-08-11
- Metabolic Plasticity of Glioblastoma Cells in Response to DHODH Inhibitor BAY2402234 Treatment
Journal: Metabolites
Date: 2024-07-01
- Exploring the sources and potential applications of marine collagenases
Journal: Biocatalysis and Agricultural Biotechnology
Date: 2024-06-11
- Interleukin-11/IL-11 Receptor Promotes Glioblastoma Cell Proliferation, Epithelial-Mesenchymal Transition, and Invasion
Journal: Brain Sci
Date: 2024-01-11
- A New Systemic Disease Mouse Model for Glioblastoma Capable of Single-Tumour-Cell Detection
Journal: Cells
Date: 2024-01-01
- Signaling pathways underlying TGF-β mediated suppression of IL-12A gene expression in monocytes
Journal: Mol Immunol
Date: 2024-01-01
- Molecular Mechanisms Associated with the Inhibitory Role of Long Chain n-3 PUFA in Colorectal Cancer
Journal: Integr Cancer Ther
Date: 2024-01-01
- The Prognostic Value of Preoperative Inflammatory Markers for Pathological Grading of Glioma Patients
Journal: Technol Cancer Res Treat
Date: 2024-01-01
- A New Era of Integration between Multiomics and Spatio-Temporal Analysis for the Translation of EMT towards Clinical Applications in Cancer
Journal: Cells
Date: 2023-11-01
- Dynamics of transforming growth factor β signaling and therapeutic efficacy
Journal: Growth Factors
Date: 2023-10-01
- Label-free macrophage phenotype classification using machine learning methods
Journal: Sci Rep
Date: 2023-03-01
- The Interleukin-11/IL-11 Receptor Promotes Glioblastoma Survival and Invasion under Glucose-Starved Conditions through Enhanced Glutaminolysis.
Journal: International Journal Molecular Science
Date: 2023-02-01
- Blocking Muscarinic Receptor 3 Attenuates Tumor Growth and Decreases Immunosuppressive and Cholinergic Markers in an Orthotopic Mouse Model of Colorectal Cancer
Journal: Int J Mol Sci.
Date: 2022-12-01
- The comparative anti-cancer effects of krill oil and oxaliplatin in an orthotopic mouse model of colorectal cancer
Journal: Nutr Metab (Lond)
Date: 2022-03-01
- Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression
Journal: Int J Mol Sci
Date: 2022-03-01
- Cortical tension initiates the positive feedback loop between cadherin and F-actin
Journal: Biophys
Date: 2022-02-11
- Krill oil supplementation reduces the growth of CT-26 orthotopic tumours in Balb/c mice. Jayathilake AG, Kadife E, Kuol N, Luwor RB, Nurgali K, Su XQ
Journal: BMC Complement Med Ther
Date: 2022-02-01
- The effects of the dietary compound L-sulforaphane against respiratory pathogens
Journal: Int J Antimicrob Agents
Date: 2021-12-01
- Dinuclear orthometallated gold(I)-gold(III) anticancer complexes with potent in vivo activity through an ROS-dependent mechanism
Journal: Metallomics
Date: 2021-07-11
- Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer
Journal: Int J Mol Sci
Date: 2021-07-01
- EGFRvIII Promotes Cell Survival during Endoplasmic Reticulum Stress through a Reticulocalbin 1-Dependent Mechanism
Journal: Cancers (Basel)
Date: 2021-03-01
- Elucidating the role of long intergenic non-coding RNA 339 in human endometrium and endometriosis
Journal: Mol Hum Reprod
Date: 2021-02-11
- Examination of Novel Immunomodulatory Effects of L-Sulforaphane
Journal: Nutrients
Date: 2021-02-11
- Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression
Journal: BMC Cmplement Med Ther
Date: 2020-12-11
- Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma
Journal: Sci Rep
Date: 2020-10-11
- Serum microRNA is a biomarker for post-operative monitoring in glioma
Journal: J Neurooncol
Date: 2020-09-11
- Novel additive for sperm cryopreservation media: Holotheria parva coelomic cavity extract protects human spermatozoa against oxidative stress-A pilot study
Journal: Andrologia
Date: 2020-07-11
- In Vitro and In Vivo Toxicity and Biodistribution of Paclitaxel-Loaded Cubosomes as a Drug Delivery Nanocarrier: A Case Study Using an A431 Skin Cancer Xenograft Model
Journal: ACS Applied Bio Materials
Date: 2020-06-08
- Antitumor and Antiangiogenic Properties of Gold(III) Complexes Containing Cycloaurated Triphenylphosphine Sulfide Ligands
Journal: Inorg Chem
Date: 2020-04-11
- Therapeutic Reversal of Radiotherapy Injury to Pro-fibrotic Dysfunctional Fibroblasts In Vitro Using Adipose-derived Stem Cells
Journal: Plast Reconstr Surg Glob Open
Date: 2020-03-11
- Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma
Journal: Cancer Invest
Date: 2019-12-11
- Potent and Selective Cytotoxic and Anti-inflammatory Gold(III) Compounds Containing Cyclometalated Phosphine Sulfide Ligands
Journal: Chemistry
Date: 2019-11-27
- Krill oil extract suppresses the proliferation of colorectal cancer cells through activation of caspase 3/9
Journal: Nutr Metab (Lond)
Date: 2019-08-11
- The Potential Role of Interleukin-11 in Epithelial Ovarian Cancer
Journal: Journal of Cancer Science and Clinical Therapeutics
Date: 2019-02-08
- Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer.
Journal: Cancers
Date: 2019-02-08
- Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance
Journal: Exp Cell Res
Date: 2019-01-11
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Journal: Onco Targets Ther
Date: 2019-01-11
- Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs
Journal: Transl Oncol
Date: 2018-12-11
- Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth
Journal: Cancers (Basel)
Date: 2018-12-11
- Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics
Journal: Exp Cell Res
Date: 2018-10-11
- The role of interleukin-6-STAT3 signalling in glioblastoma
Journal: Oncol Lett
Date: 2018-10-11
- Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide
Journal: J Neurosurg
Date: 2018-09-11
- Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition
Journal: Acta Oncol
Date: 2018-08-11
- Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer
Journal: ACS Applied Materials & Interfaces
Date: 2018-07-01
- Peripheral biomarkers in glioblastoma patients—is it all just HOTAIR?
Journal: NCRI
Date: 2018-06-11
- The emerging use of bioluminescence in medical research
Journal: Biomed Pharmacother
Date: 2018-05-11
- Momelotinib reduces cancer stem cell load leading to a decreased tumor burden and a prolonged disease-free remission period in a mouse model of human ovarian cancer
Journal: Oncotarget
Date: 2018-03-12
- Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
Journal: Oncotarget
Date: 2018-03-01
- A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker
Journal: PLoS One
Date: 2018-02-11
- Effects of High and Low EphB4 Receptor Expression on Colorectal Cancer Cell Behaviour and Tumour Growth, Vascularisation and Composition
Journal: Acta Oncol
Date: 2018-01-12
- Cancer exosomes in cerebrospinal fluid
Journal: Transl Cancer Res
Date: 2017-10-11
- STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
Journal: Mol Cell Endrocrinol
Date: 2017-08-11
- Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling
Journal: Scientific Reports
Date: 2017-04-12
- miRNA expression profiling of cerebrospinal fluid in patients with aneurysmal subarachnoid hemorrhage
Journal: J Neurosurg
Date: 2017-04-11
- The emergent role of exosomes in glioma
Journal: J Clin Neurosci
Date: 2017-01-11
- Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growth
Journal: Nucleic Acids Res
Date: 2016-09-11
- Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.
Journal: Scientific Reports
Date: 2016-07-08
- Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib
Journal: Med Oncol
Date: 2016-05-11
- MicroRNA as potential biomarkers in Glioblastoma
Journal: J Neurooncol
Date: 2015-11-11
- The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells
Journal: Oncotarget
Date: 2015-08-11
- A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
Journal: Molecular Cancer
Date: 2015-08-01
- SPSB1, a Novel Negative Regulator of the Transforming Growth Factor-β Signaling Pathway Targeting the Type II Receptor
Journal: J Biol Chem
Date: 2015-07-11
- Using bioluminescence imaging in glioma research
Journal: J Clin Neurosci
Date: 2015-05-11
- Mouse models of glioma
Journal: Epub
Date: 2015-02-11
- Single live cell TGF-β signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF-β-Smad3 activity
Journal: Mol Cancer
Date: 2015-02-11
- Enhanced activation of STAT3 in ascites-derived recurrent ovarian tumors: inhibition of cisplatin-induced STAT3 activation reduced tumorigenicity of ovarian cancer by a loss of cancer stem cell-like characteristics.
Journal: Journal of Cancer Stem Cell Research
Date: 2015-01-01
- The role of STAT3 signaling in mediating tumor resistance to cancer therapy
Journal: Curr Drug Targets
Date: 2014-12-11
- Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFkB-mediated induction of MMP2.
Journal: Cancer Letters
Date: 2014-11-11
- Expression of the adaptor protein Tks5 in human cancer: prognostic potential
Journal: Oncol Rep
Date: 2014-09-11
- Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity
Journal: Cancer Biol Ther
Date: 2014-05-11
- Targeted disruption of JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden.
Journal: Frontiers in Oncology
Date: 2014-05-01
- Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden
Journal: BMC Cancer
Date: 2014-05-01
- Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling
Journal: Nat Commun
Date: 2014-03-11
- Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme
Journal: J Clin Neurosci
Date: 2013-09-11
- Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically
Journal: Cancer Cell
Date: 2013-08-11
- The role of Stat3 in glioblastoma multiforme
Journal: J Clin Neurosci
Date: 2013-07-11
- Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo
Journal: Oncogene
Date: 2013-05-11
- Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Journal: Molecular Cancer
Date: 2013-03-11
- Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemo resistant ovarian tumors
Journal: PloS One
Date: 2012-10-11
- Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation
Journal: Growth Factors
Date: 2012-08-11
- New reagents for improved in vitro and in vivo examination of TGF-β signalling
Journal: Growth Factors
Date: 2011-10-11
- Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib
Journal: Cancer Lett
Date: 2011-07-11
- The EGFRvIII variant in glioblastoma multiforme
Journal: J Clin Neurosci
Date: 2009-06-11
- Antibodies specifically targeting a locally misfolded region of tumor associated EGFR
Journal: Proc Natl Acad Sci USA
Date: 2009-03-11
- Transforming growth factor-beta (TGF-beta) and brain tumours
Journal: J Clin Neurosci
Date: 2008-08-11
- Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab
Journal: Cancer Res
Date: 2007-09-11
- Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells
Journal: Oncogene
Date: 2006-01-11
- Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity
Journal: Clin Cancer Res
Date: 2005-09-11
- The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression
Journal: Oncogene
Date: 2005-06-11
- The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR
Journal: Oncogene
Date: 2004-08-11
- Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
Journal: Acad Sci USA
Date: 2003-12-11
- Growth Suppression of Intracranial Xenografted Glioblastomas Overexpressing Mutant Epidermal Growth Factor Receptors by Systemic Administration of Monoclonal Antibody (mAb) 806, a Novel Monoclonal Antibody Directed to the Receptor
Journal: Cancer Res
Date: 2001-07-12
- Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR
Journal: Cancer Res
Date: 2001-07-11
Dr Sushma Rao
PhD, MSc, BSc
Senior Research Fellow
Dr. Sushma Rao is mass spectrometry applications specialist with extensive experience in proteomics and metabolomics technologies. She brings in a unique skill set of integrating molecular biology, biotechnology, mass spectrometry and data analysis techniques. She completed a PhD University of Melbourne in proteomics/metabolomics mass spectrometry, studying the proteome and metabolome of rice suspension cell cultures during abiotic stress and identified signalling pathways that were most affected. After completing her PhD, she transitioned to apply her skill set in biomedical research. Dr Rao has held previous appointments at Children’s Medical Research Institute – Sydney and the National University of Singapore. Her role prior to commencing at the at FECRI was in the Mass Spectrometry team, leading Proteomic projects for the South Australian Health and Medical Research Institute. In this role she worked accross various research projects and clinical trials to identify plasma protein biomarkers in research areas ranging from, but not limited to, chronic myeloid leukemia, prostate cancer, cardiovascular research, stroke research, breast cancer, stem-cell research and neurogenetic disorders research. Dr. Rao is very excited to be a part of the amazing team of scientists at FECRI. She will be starting a Multiple Myeloma research project utilising proteomics to study the complexity of this difficult cancer. Additionally, she will be leading mass spectrometry applications across multiple project streams at the Institute, focused on proteomics and metabolomics.
Publications
- Proteomic Effects of Colchicine on Human Macrophages Loaded With Oxidised Low-Density Lipoprotein Cholesterol
Journal: Heart Lung Circ
Date: 2025-09-01
- Supramolecular Guest Exchange in Cucurbit[7]uril for Bioorthogonal Fluorogenic Imaging across the Visible Spectrum
Journal: ACS Cent Sci
Date: 2024-10-08
- Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival
Journal: Proc Natl Acad Sci USA
Date: 2024-10-01
- The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits
Journal: Journal of Biomedical Science
Date: 2024-02-01
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: 2022-10-01
- Epithelial-to-mesenchymal transition as a potential target for antineoplastic therapies.
Journal: J Cancer Clin Trials
Date: 2015-01-06
Dr Sharon Olsen
BSc (Hons) PhD
Laboratory Manager and JG King Research Fellow
Sharon joined the Institute in May 2003. She has worked in the field of cancer research for her entire career. Sharon graduated with a Bachelor of Science degree (Honours) and a PhD from the University of Melbourne. While at St. Vincent's Institute of Medical Research, Melbourne, her PhD studied parathyroid hormone-related protein and the biology of cancer. She then traveled to Canada to work on chemotherapy resistance by multi drug resistance protein at the Cancer Research Laboratories, Queen’s University, Kingston, Ontario, prior to her return to Australia.
Publications
- Multiple membrane-associated tryptophan residues contribute to the transport activity and substrate specificity of the human multidrug resistance protein, MRP1
Journal: J Biol Chem
Date: 2022-12-11
- THE ROLE OF T CELLS IN THE IMMUNE REGULATION OF LANGERHANS CELL HISTIOCYTOSIS (LCH)
Journal: Pediatric Blood & Cancer
Date: 2015-11-08
- Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.
Journal: PLoS One
Date: 2014-10-01
- Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport
Journal: J Biol Chem
Date: 2001-05-06
- PTHrP and cell division: expression and localization of PTHrP in a keratinocyte cell line (HaCaT) during the cell cycle
Journal: J Cell Physiol
Date: 1997-12-06
- Identification of a cell surface protein with a role in stimulating human keratinocyte proliferation, expressed during development and carcinogenesis
Journal: J Invest Dermatol
Date: 1997-08-06
- Parathyroid hormone-related protein and human papillomavirus in gynecological tumors
Journal: Int J Cancer
Date: 1994-02-06
Dr Monirul Islam
BSc (Hons), MSc (PhD)
Senior Scientist (Molecular Biology)
Dr. Monirul Islam joined the Institute in July 2003. Monirul obtained his Bachelor (Hons) and Master degrees in Biochemistry from the University of Dhaka, Bangladesh and his PhD in Molecular Biology from the medical faculty of Nagoya University in Japan. Before joining the Institute, Monirul was working as research associate at the Southern Methodist University, Texas, USA. Monirul also worked as a scientific officer at the Centre for Molecular Biology and Medicine, Melbourne, Australia and as a Science and Technology Agency (STA) fellow at the National Food Research Institute, Tsukuba, Japan.
Publications
- Use of Suppression Subtractive Hybridization for Viral Diagnostics
Journal: British Journal Virology
Date: 2016-05-19
- Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice.
Journal: Arch Virol
Date: 2015-09-01
- Murine hepatitis virus RNA, complete genome, strain: MHV-MI
Journal: DNA Data Bank of Japan
Date: 2010-03-12
Dr Jason Kelly
B AppSc Bio Med Sc (Hons)
Post Doctoral Researcher
Dr. Jason Kelly is a leading researcher at the Fiona Elsey Cancer Research Institute, specialising in immune responses in colorectal cancer. His PhD, investigating how the immune system interacts with bowel cancer, was published in Immunology and Cell Biology and named one of the journal’s top 10 publications of 2019. In 2018, he received a FIMSA travel grant to present his work internationally in Bangkok. A Ballarat local, Dr. Kelly spent 20 years in diagnostic pathology, where he witnessed cancer’s toll on patients and families — a formative experience that inspired his transition into cancer research. His focus on bowel cancer is driven by a deep commitment to improving early detection and patient outcomes through immunology. Beyond the lab, Dr. Kelly is an active community leader — past president of Golden Point Cricket Club and a former Grand Master of the Ballarat Hash House Harriers. In 2024, he was honoured as a Damascus College ‘Shining Light’ for his scientific achievements and community contributions. With a “Think Global, Act Local” approach, Dr. Kelly continues to push the boundaries of cancer research while remaining rooted in the Ballarat community he serves.
Publications
- Enhanced Expression of Mitochondrial Magmas Protein in Ovarian Carcinomas: Magmas Inhibition Facilitates Antitumour Effects, Signifying a Novel Approach for Ovarian Cancer Treatment
Journal: Cells
Date: 2025-04-01
- Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
Journal: Cancer Cell International
Date: 2023-02-01
- Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice
Journal: Int J Mol Sci
Date: 2023-02-01
- A Modified MTS Proliferation Assay for Suspended Cells to Avoid the Interference by Hydralazine and β-Mercaptoethanol
Journal: Assay Drug Dev Technol
Date: 2021-04-11
- A Role for MAIT Cells in Colorectal Cancer
Journal: Frontiers in Immunology
Date: 2020-05-01
- Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity
Journal: Clinical Immunology
Date: 2020-04-01
- Chronically stimulated human MAIT cells are unexpectedly potent IL-13 producers
Journal: Immunology & Cell Biology 2019
Date: 2019-07-01
- Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failure.
Journal: Journal American Heart Assoc.
Date: 2017-06-01
Dr Arpita Poddar
PhD
Post Doctoral Research Fellow
Dr Arpita Poddar graduated with her PhD in 2021 at RMIT University and the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Melbourne, where she worked on the application of nanoparticles in cancer treatment. An interdisciplinary researcher – her interests are at the interface of materials science, biology and cancer research. Working in collaboration with NHMRC clinical trials centre in the University of Sydney, Graz University of Technology, Austria, the ALBA Synchrotron, Barcelona and the Elettra Sincrotrone, Italy, she developed non-viral alternatives using nanotech to target prostate cancer cells for gene therapy. She has been a recipient of several prestigious Scholarships/bursaries including CSIR-UGC National Eligibility (Govt of India), CSIRO-RMIT research and RMIT-HDR talent award (PhD program), Top Downloaded Paper 2018-2019 and the Australian Nanotechnology Network travel award (twice) to visit and work in Europe. Dr Poddar has since worked in the Walter and Eliza Hall Institute of Medical Research, Melbourne, on understanding the structural biology of genes involved in Alzheimer’s Disease. She has held research fellowship at Monash University where she studied nanomaterials and their interaction with biomolecules. Dr Poddar has established novel nanomaterials as viable, physiologically stable and facile non-viral gene therapy systems, and she is currently applying the delivery systems across different cancer streams with a particular focus on triple negative breast cancer.
Publications
- Juxtamembrane Mimic Peptide Loaded Injectable Sodium Alginate/Bioglass Bioactive Hydrogel for Suppressing Tumor Recurrence in Post-Breast-Conserving-Surgery Treatment
Journal: ACS Appl Bio Mater
Date: 2026-08-21
- Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma
Journal: Cancers
Date: 2026-07-21
- Nanotechnology in the Generation and Analysis of Single Cells
Journal: Springer Nature
Date: 2026-05-25
- Recent Developments in Single-Cell Transcriptomics
Journal: Springer Nature
Date: 2026-05-25
- Synthetic Biology in Precision Medicine and Nanotechnology
Journal: Springer Nature
Date: 2026-05-25
- Synthetic Biology for Cancer Stem Cells
Journal: Springer Nature
Date: 2026-05-25
- Phase Characterization and Bioactivity Evaluation of Nucleic Acid-Encapsulated Biomimetically Mineralized ZIF-8
Journal: ACS Appl Mater Interfaces
Date: 2025-01-11
- Metal Organic Frameworks (MOFs) as non-viral gene delivery vehicles for gene therapy in prostate cancer
Journal: RMIT University
Date: 2024-11-12
- Impact of Ligand Concentration on the Properties of Nucleic-Acid-Encapsulated MOFs and Inflammation Modulation in Prostate Cancer Cells
Journal: ACS Appl Bio Mater
Date: 2024-11-01
- Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
Journal: Cells
Date: 2024-10-01
- Advances in CRISPR/Cas systems-based cell and gene therapy
Journal: Epub
Date: 2024-08-11
- The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits
Journal: Journal of Biomedical Science
Date: 2024-02-01
- Editorial: Non-viral vectors for gene therapy/nucleic acid delivery
Journal: Front Bioeng Biotechnol,
Date: 2023-10-11
- Targeting telomerase utilizing zeolitic imidazole frameworks as non-viral gene delivery agents across different cancer cell types
Journal: Biomater Adv
Date: 2023-06-11
- A quest for cytocompatible metal organic frameworks in non-viral gene therapy: relevance of zeolitic imidazolate framework-8
Journal: Biomaster Biosyst
Date: 2022-10-01
- Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Journal: Current Oncology
Date: 2022-10-01
- ZIF-C as non-viral delivery system for CRISPR/Cas9 mediated hTERT knockdown in cancer cells
Journal: ChemRxiv
Date: 2021-08-11
- Outside Front Cover:(Biotechnology Journal 3/2021)
Journal: (Biotechnology Journal 16
Date: 2021-03-12
- ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer
Journal: Chemical Communications
Date: 2020-10-11
- Multimodal Imaging and Soft X‐Ray Tomography of Fluorescent Nanodiamonds in Cancer Cells
Journal: Biotechnology Journal
Date: 2020-09-11
- Modulation of metal-azolate frameworks for the tunable release of encapsulated glycosaminoglycans
Journal: Chemical Science
Date: 2020-07-11
- Real-time detection and identification of nematode eggs genus and species through optical imaging
Journal: Scientific Reports
Date: 2020-04-11
- ZIF polymorphs for Nucleic Acid Delivery and Targeted Knockdown of Gene Expression in Prostate Cancer
Journal: ChemRxiv
Date: 2020-02-11
- MOF based nucleic acid delivery for knockdown of gene expression in Prostate Cancer
Journal: ChemRxiv
Date: 2020-02-11
- Encapsulation, Visualization and Expression of Genes with Biomimetically Mineralized Zeolitic Imidazolate Framework‐8 (ZIF‐8)
Journal: Small
Date: 2019-09-11
- A Novel Gene Delivery Approach Using Metal Organic Frameworks in Human Islet-Derived Progenitor Cells
Journal: Progenitor Cells
Date: 2019-07-11
- Functionalization of elongated tetrahexahedral Au nanoparticles and their antimicrobial activity assay
Journal: ACS Appl Mater Interfaces
Date: 2019-03-11
- Intrinsic fluorescence from cellulose nanofibers and nanoparticles at cell friendly wavelengths
Journal: APL Photonics
Date: 2019-02-11
Dr Farah Ahmady-Nield
BBioMedSc (Hons) PhD
Post Doctoral Researcher
Dr. Farah Ahmady is a passionate cancer researcher and immunologist with a strong foundation in molecular and cell biology. She began her academic journey with a Bachelor of Biomedical Science (Hons), investigating the role of zinc in type 2 diabetes, and went on to complete her PhD at the Fiona Elsey Cancer Research Institute in 2022 through a prestigious HDR Scholarship. Her doctoral research explored immune cell subsets in ovarian cancer, presented at key national and international conferences including the 2019 Keystone Symposia on Cancer Metastasis. Now a postdoctoral research fellow, Dr. Ahmady focuses on tumour-immune interactions and the microenvironment in glioblastoma and triple-negative breast cancers, with work published in leading journals. She is also expanding into pancreatic cancer research. Dr. Ahmady contributes to collaborative studies in renal and prostate cancer and actively co-supervises Honours and PhD students. A strong advocate for women in STEM, she is committed to mentoring future scientists. A proud member of the Ballarat community, she values public engagement and frequently shares her research with local audiences. In 2024, she was recognised among Ballarat’s 40 Under 40, honouring her scientific leadership and deep community commitment.
Publications
- Mechanisms of Immune Cell Dysregulation in Pancreatic Ductal Adenocarcinoma
Journal: Biology (Basel)
Date: 2026-09-02
- Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma
Journal: Cancers
Date: 2026-07-21
- Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment
Journal: Immunol Cell Biol
Date: 2026-07-21
- The Signaling Networks of TIM-3, TGF-β and STING in Glioblastoma
Journal: Cells
Date: 2026-05-29
- Correlation of Galectin Family Expression with Glioblastoma Progression and Survival
Journal: Int J Mol Sci
Date: 2025-12-01
- The Role of TIM-3 in Glioblastoma Progression
Journal: Cells
Date: 2025-02-01
- In-Silico and Functional Characterisation of Nematode Galectin-3 and Galectin-9
Journal: Parasitological Science 2025
Date: 2025-01-01
- Impact of Ligand Concentration on the Properties of Nucleic-Acid-Encapsulated MOFs and Inflammation Modulation in Prostate Cancer Cells
Journal: ACS Appl Bio Mater
Date: 2024-11-01
- Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
Journal: Cells
Date: 2024-10-01
- Advances in CRISPR/Cas systems-based cell and gene therapy
Journal: Epub
Date: 2024-08-11
- The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits
Journal: Journal of Biomedical Science
Date: 2024-02-01
- Coronary Artery Disease: Why We should Consider the Y Chromosome
Journal: heart, Lung, and Circulation
Date: 2018-08-06
- The penetration of methanol into bovine cardiac and hepatic tissues is faster than ethanol and formalin
Journal: Eur J Histochem
Date: 2018-02-06
Dr Ruth Escalona
PhD
Post Doctoral Research Fellow
Publications
- Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion
Journal: Journal of Biomedical Science
Date: 2026-06-26
- Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion
Journal: J Biomed Sci
Date: 2026-06-21
- Enhanced Expression of Mitochondrial Magmas Protein in Ovarian Carcinomas: Magmas Inhibition Facilitates Antitumour Effects, Signifying a Novel Approach for Ovarian Cancer Treatment
Journal: Cells
Date: 2025-04-01
- Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets
Journal: Cancers (Basel)
Date: 2024-12-12
- In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.
Journal: Cancers
Date: 2023-05-01
- Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
Journal: Cancer Cell International
Date: 2023-02-01
- Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment
Journal: Frontiers in Oncology
Date: 2022-01-11
- TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
Journal: BMC Cancer
Date: 2020-10-08
- Tumour Microenvironment and Metabolic Plasticity in Cancer and Cancer Stem Cells: Perspectives on Metabolic and Immune Regulatory Signatures in Chemoresistant Ovarian Cancer Stem Cells.
Journal: Seminars in Cancer Biology
Date: 2018-07-08
- Paclitaxel-loaded self-assembled lipid nanoparticles as targeted drug delivery systems for the treatment of aggressive ovarian cancer
Journal: ACS Applied Materials & Interfaces
Date: 2018-07-01
- The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.
Journal: International Journal of Molecular Sciences Review
Date: 2018-01-01
- Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling
Journal: Scientific Reports
Date: 2017-04-12
- Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells
Journal: Scientific Reports
Date: 2016-07-01
- Distinct molecular signature of recurrent ovarian tumor cells isolated from the ascites of advanced-stage serous ovarian cancer patients.
Journal: Journal of Cancer Stem Cell Research
Date: 2014-10-01
- Targeted disruption of JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden.
Journal: Frontiers in Oncology
Date: 2014-05-01
- Effects of TGFβ2 on wild type and Tgfbr3 knockout mouse fetal testis
Journal: Biol Reprod
Date: 2013-03-08
- Fetal testis dysgenesis and compromised Leydig cell function in TGFBR3 (betaglycan) knockout mice
Journal: Biol Reprod
Date: 2010-01-08
- Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells
Journal: Mol Endocrinol
Date: 2009-01-11
- Reducing betaglycan expression by RNA interference (RNAi) attenuates inhibin bio-activity in LβT2 gonadotrope cells
Journal: Mol Cell Endocrinol
Date: 2009-01-08
- Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan
Journal: Endocrinol
Date: 2007-11-08
- Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line
Journal: Endocrinol
Date: 2006-07-12
- Labour-associated regulation of prostaglandin E and F synthesis and action in the ovine amnion and cervix
Journal: J Soc Gynecol Invest
Date: 2006-01-08
- Prostaglandin E and F receptor expression and myometrial sensitivity at labor onset in the sheep
Journal: Biol Reprod
Date: 2005-04-08
- Pituitary cell lines and their endocrine applications
Journal: Mol Cell Endocrinol
Date: 2004-12-08
- Changes in the expression of prostaglandin E and F synthases at induced and spontaneous labour onset in the sheep
Journal: J Endocrinol
Date: 2004-03-08
Dylan King
BMedSci (Hons)
Tissue Bank Coordinator and Research Assistant
Dylan King is a researcher at the Fiona Elsey Cancer Research Institute with a passion for immunology, particularly the role of innate immune cells in cancer therapy. His research journey began as an undergraduate at La Trobe University, where he studied Biomedical Science and Biochemistry. In 2009, he was awarded an Undergraduate Research Opportunities Scholarship, enabling him to undertake part-time research at the Monash Institute of Pharmaceutical Sciences throughout his degree. In his third year, he achieved first-author publication in the prestigious chemistry journal Langmuir. In 2011, Dylan completed a Bachelor of Medical Science (Hons) at the University of Melbourne through the Murdoch Children’s Research Institute, focusing on dendritic cell-based immunotherapy for neuroblastoma in paediatric patients. He went on to commence a PhD at the Olivia Newton-John Cancer Research Institute, investigating immune regulation of antibody effector mechanisms in cancer therapy. As an APA Scholarship recipient, he was also awarded a Harold Mitchell Foundation Travel Fellowship to present at the IBC Antibody Engineering and Therapeutics Conference in Los Angeles in 2014. In 2016, Dylan relocated to Ballarat, launching a window and gutter cleaning business to balance work with raising his young family. Introduced to FECRI by two clients, he patiently waited for the right opportunity to join the Institute’s research team — a move driven by his long-standing commitment to advancing cancer immunology. Today, Dylan brings both his scientific expertise and lived experience to FECRI’s research programs, motivated by a belief that the immune system holds the key to improving cancer treatments and outcomes.
Publications
- Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion
Journal: Journal of Biomedical Science
Date: 2026-06-26
- Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion
Journal: J Biomed Sci
Date: 2026-06-21
- Current Development of Monoclonal Antibodies in Cancer Therapy.
Journal: (book) Current Immunotherapeutic Strategies in Cancer | Springer Nature Link
Date: 2020-09-13
- Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Journal: The Biochem Journal
Date: 2018-07-13
- Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Journal: MAbs
Date: 2016-05-08
- Glyceride lipid formulations: molecular dynamics modeling of phase behavior during dispersion and molecular interactions between drugs and excipients.
Journal: Pharmaceutical Research
Date: 2013-12-08
- Using molecular dynamics to study liquid phase behavior: simulations of the ternary sodium laurate/sodium oleate/water system.
Journal: Langmuir: the ACF journal of surfaces and colloids
Date: 2011-09-08
Dr Jenée Mitchell
BAppSc (Hons), PhD
Don Mulhallen Cancer Research Fellow
Following graduation from Federation University with a Bachelor of Applied Science (Hons), Jenée joined the laboratory in 2012 as part of the team working on histiocytic diseases and completing her PhD this on the role of T cells in the immune regulation of Langerhans cell histiocytosis in 2019. She was appointed Post Doctorate Researcher at the Institute in 2020 and continues her work into Langerhans cell histiocytosis.
Publications
- Does CD1a Expression Influence T Cell Function in Patients With Langerhans Cell Histiocytosis?
Journal: Front. Immunol
Date: 2022-12-08
- Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions
Journal: Front Pediatr.
Date: 2022-06-01
- Langerhans cell histiocytosis: A malignant myeloid neoplasm or disorder of immune regulation?
Journal: Acta Paediatrica
Date: 2021-06-01
- Patients with both Langerhans cell histiocytosis and Crohn’s disease highlight a common role of interleukin-23
Journal: Acta Paediatr.
Date: 2021-04-01
- When Langerhans met Crohn- intestinal inflammation in disguise
Journal: Acta Paediatrica
Date: 2020-09-11
- Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity
Journal: Clinical Immunology
Date: 2020-04-01
- Co-Expression of CD56 and Production of Transforming Growth Factor Beta By Foxp3 Regulatory T Cells from Langerhans Cell Histiocytosis Lesions
Journal: Blood
Date: 2018-12-08
- Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis
Journal: Scientific Reports
Date: 2018-12-01
- A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis
Journal: Clinical Immunology
Date: 2018-06-01
- THE ROLE OF T CELLS IN THE IMMUNE REGULATION OF LANGERHANS CELL HISTIOCYTOSIS (LCH)
Journal: Pediatric Blood & Cancer
Date: 2015-11-08
- Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.
Journal: PLoS One
Date: 2014-10-01
- Consumption of a low glycaemic index diet in late life extends lifespan of Balb/c mice with differential effects on DNA damage
Journal: Longevity & Healthspan
Date: 2013-03-08
Professor Stuart Berzins
BSc (Hons) PhD GCUT
Visiting Research Fellow
Publications
- Expression of CD38 on resting peripheral iNKT cells defines an immature subpopulation with distinct functionality in humans.
Journal: Immunology & Cell Biology
Date: 2026-02-08
- The changing immune landscape of innate-like T cells and other innate cells throughout life
Journal: Immunol Cell Biol.
Date: 2026-01-01
- Thymic development of human natural killer T cells: recent advances and implications for immunotherapy
Journal: Front. Immunol
Date: 2024-08-13
- Divergent molecular networks program functionally distinct CD8+ skin-resident memory T cells
Journal: Science
Date: 2023-12-01
- A three-stage developmental pathway for human Vγ9Vδ2 T cells within the postnatal thymus
Journal: Sci Immunol
Date: 2023-07-12
- A high-dimensional cytometry atlas of peripheral blood over the human life span
Journal: Immunol Cell Biol.
Date: 2022-11-01
- Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions
Journal: Front Pediatr.
Date: 2022-06-01
- Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral retention of tissue-resident lymphocytes
Journal: J Exp Med
Date: 2022-01-01
- The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence
Journal: Cell Commun Signal
Date: 2021-05-11
- Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge
Journal: Nature Reviews Immunology
Date: 2020-06-01
- High CD26 and Low CD94 Expression Identifies an IL-23 Responsive Vδ2+ T Cell Subset with a MAIT Cell-like Transcriptional Profile
Journal: Cell Reports
Date: 2020-06-01
- A Role for MAIT Cells in Colorectal Cancer
Journal: Frontiers in Immunology
Date: 2020-05-01
- Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity
Journal: Clinical Immunology
Date: 2020-04-01
- A divergent transcriptional landscape underpins the development and functional branching of MAIT cells
Journal: Sci Immunol.
Date: 2019-11-01
- Chronically stimulated human MAIT cells are unexpectedly potent IL-13 producers
Journal: Immunology & Cell Biology 2019
Date: 2019-07-01
- Divergent SATB1 expression across human life-span and tissue compartments
Journal: Immunology & Cell Biology
Date: 2019-05-08
- Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis
Journal: Scientific Reports
Date: 2018-12-01
- A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis
Journal: Clinical Immunology
Date: 2018-06-01
- Temporal Regulation of Natural Killer T Cell Interferon Gamma Responses by β-Catenin-Dependent and Independent Wnt Signaling.
Journal: Frontiers in Immunology Volume 9- Article 483
Date: 2018-03-01
- Human blood MAIT cell subsets defined using MR1 tetramers.
Journal: Immunology and Cell Biology
Date: 2018-03-01
- Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failure.
Journal: Journal American Heart Assoc.
Date: 2017-06-01
- A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage
Journal: Nat Immunol
Date: 2016-09-01
- An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia.
Journal: International Immunopharmacol
Date: 2015-04-11
- Natural killer T cells: drivers or passengers in preventing human disease?
Journal: National Review of Immunology
Date: 2014-09-01
- The glucocorticoid receptor 1A3 promoter correlates with high sensitivity to glucocorticoid-induced apoptosis in human lymphocytes.
Journal: Immunol Cell Biol
Date: 2014-07-01
- Acute exercise leads to regulation of telomere-associated genes and microRNA expression in immune cells.
Journal: PLoS One
Date: 2014-04-01
- Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
Journal: Clin Exp Immunol
Date: 2014-01-08
- Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(-) subsets.
Journal: Clin Exp Immunol
Date: 2013-04-08
- The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens
Journal: Immunity
Date: 2012-09-08
- The NF-κB1 transcription factor prevents the intrathymic development of CD8 T cells with memory properties.
Journal: EMBO J
Date: 2011-11-11
- Presumed guilty: natural killer T cell defects and human disease.
Journal: Nt Rev Immunol
Date: 2011-02-08
- Lessons learned from an unusual presentation of CD3+, CD56- T-cell large granular lymphocyte leukemia.
Journal: Journal of Clinical Oncologoy
Date: 2010-10-08
- Transcriptional regulation of lymphocyte development. Developing NKT cells need their (E) protein.
Journal: Immunol Cell Biology
Date: 2010-05-08
- An NZW-derived interval on chromosome 7 moderates sialadenitis, but not insulitis in congenic nonobese diabetic mice.
Journal: Journal of Immunology
Date: 2010-01-08
- Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.
Journal: Leukemia
Date: 2010-01-08
- Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family.
Journal: Clin Exp Immunol
Date: 2009-05-08
- NKT cell development in the absence of the autoimmune regulator gene (Aire).
Journal: European Journal of Immunology
Date: 2008-09-08
- Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population.
Journal: Proc Natl Acad Sci U S A
Date: 2008-08-08
- Peripheral NK1.1 NKT cells are mature and functionally distinct from their thymic counterparts.
Journal: Journal of Immunol
Date: 2007-11-08
- Control points in NKT-cell development.
Journal: Nat Review Immunol
Date: 2007-08-08
- Retraction: Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors.
Journal: Nat Immunol
Date: 2007-08-08
- Antigen challenge inhibits thymic emigration.
Journal: J Immunol
Date: 2006-04-08
- Long-term retention of mature NK1.1+ NKT cells in the thymus.
Journal: J Immunol
Date: 2006-04-08
- Localization of Idd11 is not associated with thymus and nkt cell abnormalities in NOD mice.
Journal: Diabetes
Date: 2005-12-08
- Differential antitumor immunity mediated by NKT cell subsets in vivo.
Journal: J Exp Med
Date: 2005-11-08
- The influence of CD1d in postselection NKT cell maturation and homeostasis.
Journal: J Immunol
Date: 2005-09-08
- The cellular mechanism of Aire control of T cell tolerance.
Journal: Immunity
Date: 2005-08-08
- Activation of thymic regeneration in mice and humans following androgen blockade.
Journal: Journal of Immunology
Date: 2005-08-08
- Expression of the gastric H/K-ATPase alpha-subunit in the thymus may explain the dominant role of the beta-subunit in the pathogenesis of autoimmune gastritis.
Journal: Autoimmunity
Date: 2005-06-08
- Are we really on the right TRAIL?
Journal: Immunol Res
Date: 2005-06-08
- Working with NKT cells–pitfalls and practicalities.
Journal: Curr Opin Immunol
Date: 2005-06-08
- Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples.
Journal: European Journal Immunology
Date: 2005-04-08
- Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors
Journal: Nat Immunol
Date: 2004-06-08
- Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies.
Journal: Immunol Cell Biology
Date: 2004-06-08
- Parallels and distinctions between T and NKT cell development in the thymus.
Journal: Immunol Cell Biol
Date: 2004-06-08
- Normal thymocyte negative selection in TRAIL-deficient mice.
Journal: Journal Exp Med
Date: 2003-08-08
- T-cell compartments of prediabetic NOD mice.
Journal: Diabetes
Date: 2003-02-08
- Essential role for the lymphostromal plasma membrane Ly-6 superfamily molecule thymic shared antigen 1 in development of the embryonic adrenal gland.
Journal: Mol Cell Biol
Date: 2002-11-08
- Thymic regeneration: teaching an old immune system new tricks.
Journal: Trends Mol Med
Date: 2002-10-08
- Projection of an immunological self shadow within the thymus by the aire protein.
Journal: Science
Date: 2002-10-08
- A central role for thymic emigrants in peripheral T cell homeostasis.
Journal: Proc Natl Acad Sci U S A
Date: 1999-08-08
- Thymic shared antigen-2: a novel cell surface marker associated with T cell differentiation and activation.
Journal: Journal Immunol
Date: 1999-05-08
- The role of the thymus and recent thymic migrants in the maintenance of the adult peripheral lymphocyte pool.
Journal: J Exp Med
Date: 1998-06-08
Dr Morgan Wallace
BSc (Hons) PhD
Visiting Research Fellow
Morgan Wallace is a lecturer in Biomedical science at Federation University and an Honoarary Research Fellow at the Fiona Elsey Cancer Research Institute. Morgan has worked as a research scientist at several leading research institutes including the University of Massachusetts (USA) the Peter MacCallum Cancer Centre and St Vincent’s Institute in Melbourne. She is currently working with researchers at the Institute to investigate the role of the immune system in fighting haematological cancers including Chronic Lymphocytic Leukaemia and Multiple Myeloma.
Dr Jenny West
BSc (Hons) PhD
Visiting Research Fellow
Jenny has a background in cell biology and biochemistry and joined the Institute in 2001 before retiring in 2017. She retains a connecting with the research team as a Visiting Research Fellow in supporting and mentoring researchers in their projects.
Dr Emma Gannan
BBioMedSci(Hons) MBBS(Hons) DipAnat MS(BreastSurg) FRACS BreastSurgANZ
Collaborating Clinician- Ballarat
Dr Emma Gannan is a specialist breast surgeon. Emma has a particular interest in oncoplastic breast surgery and manages all surgical aspects of benign and malignant breast disease. Emma performs the full range of oncoplastic breast surgery, including implant reconstruction. Emma practices multi-disciplinary breast cancer care and has an interest in medical research. Emma also enjoys her role as a lecturer teaching medical students.